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Does the mode of inhalation affect the
bronchodilator response in patients with
severe COPD?
N. M. EISER, C. PHILLIPS AND P. A. WOOLER
University Hospital Lewisham, London, U.K.
Spacing devices improve lung deposition of aerosols from metered dose inhalers (MDI) but it is sometimes dicult
for dyspnoeic patients to perform maximal breaths with breath-holds needed to inhale the aerosols from them. Our
aim was to determine whether the response to bronchodilators (BD) depended on the method of inhalation.
We studied 20 patients with moderately severe chronic obstructive pulmonary disease (COPD) with a mean age
of 68 years and a mean of forced expiratory volume in 1 sec (FEV1) of 41% predicted. In a randomized, cross-over
fashion they inhaled terbutaline 1?5 mg (six puffs) followed by ipratropium 120 mg (six puffs) via MDI and
nebuhaler with either two inspirations to total lung capacity and a 10-sec breath-hold per puff or with six tidal
breaths per puff. Before and after BDs we measured FEV1, forced vital capacity (FVC), airways resistance using
interrupter method (Rint) and 6-min walking distance (6MWD). Subsequently, we re-tested nine of these patients
with the two methods of inhalation, before and after conventional doses (terbutaline 500 mgipratropium 40 mg),
then after terbutaline 1 mg and ipratropium 80 mg and finally after nebulized terbutaline 5 mg and ipratropium
500 mg to see whether there was a dose-dependent difference in effect between the two methods. Spirometry, slow
vital capacity (SVC), inspiratory capacity and shuttle walking tests were monitored.
In the original 20 patients there were highly significant improvements in all parameters after inhalers, with no
significant difference between methods of inhalation. Median improvements after BDs were: FEV1 0?221 and 0?191,
FVC 0?501 and 0?381 and 6MWD 40 m and 44 m, for maximal breaths and tidal breathing, respectively. For nine
patients, tidal and maximal breaths produced similar effects on lung function and exercise tolerance at both doses of
BDs. Nebulized BDs only improved shuttle distances slightly when compared with either method of inhalation
from MDI and spacer but had no additional effect on lung function.
In conclusion, in patients with moderately severe COPD, BDs given by metered dose inhaler via nebuhaler have
similar effects whether given by six easy tidal breaths or the more dicult two maximal breaths with breath-hold.
This holds true at small or larger doses of BD. Either method of inhaling six puffs of the BDs can be used as an
effective alternative to nebulized aerosol.
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Patients with chronic obstructive pulmonary disease
(COPD) often have diculty using inhalers. Most of the
aerosol dose impacts on the oropharynx due to both the
diculty with which many patients co-ordinate their
breathing to actuating the metered dose inhaler (MDI),
and also to the high velocity of aerosols produced by MDIs.
Thus, even with a good technique, only between 8–9% of
the inhaled dose reaches the lungs (1–3). In order toReceived 28 August 2000 and accepted in revised form 5 March
2001.
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0954-6111/01/060476+07 $35?00/0circumvent these problems, a spacing device, such as a
nebuhaler, is often recommended. By reducing the velocity
of inhaled aerosols and also by allowing more time for
patients to inhale, the lung deposition is doubled and
oropharyngeal deposition greatly reduced: from 81% to
17% (4, 5).
There is abundant evidence both from normal subjects
and from patients with airflow obstruction, that the effects
of bronchodilators (BD) inhaled from an MDI can be
significantly enhanced by the use of spacing devices (6–8).
Generally, it is suggested that two maximal breaths (8) are
taken per puff from the MDI. The manufacturers also
recommend that each breath is followed by a 10-sec breath-
hold. However, many patients, particularly those with
severe COPD, find it dicult to breath-hold for so long.
Consequently, their use of spacers may be less than# 2001 HARCOURT PUBLISHERS LTD
INHALATION MODE AND BRONCHODILATOR RESPONSE IN COPD 477optimal. In children, there is evidence that tidal breathing
through a spacing device, such as a nebuhaler or even via a
polystyrene coffee cup, may be a satisfactory method of
delivering aerosols from MDI devices (9–11). In addition,
there is a wealth of evidence showing that BDs produce
comparable effects, whether given via an MDI with spacer
or via a nebulizer. The aim of the present study was to
compare the effects on patients with severe, stable COPD of
BDs given by MDI via a spacing device (nebuhaler) using
either maximal breaths with breath-hold or tidal breathing.




Twenty-two patients with a mean age of 68 years (range 52–
82 years) were recruited from the Chest Clinic at University
Hospital Lewishan (Table 1). They all had moderate to
severe, but stable, COPD and gave a history of gradually
increasing exertional dyspnoea for 10 years or more. Their
forced expiratory volume in 1 sec (FEV1) values had been
stable during the preceding 3 months. All patients were
either current smokers of 20 pack-years or more (n=10), or
ex-smokers (n=12), and all had a chronic productive cough.
Twenty-one of the patients had a baseline FEV1 of less than
50% of predicted normal for their age, sex and height. OneTABLE 1. Patients with severe COPD (n=20)
Patient Age (yrs) Sex Predicted FEV1 (l) FEV
RR 82 M 2?06 0?
PD 62 F 1?76 0?
JG 61 F 2?41 0?
HL 64 M 2?75 0?
JT 74 F 1?65 0?
RL 76 M 2?25 1?
GD 78 M 2?41 1?
GN 76 F 1?75 0?
GS 63 F 2?01 0?
ED 70 M 2?97 1?
PB 57 F 2?04 0?
TD 62 M 3?46 1?
TF 72 M 2?62 0?
EL 52 M 3?86 2?
AW 80 M 2?16 0?
TD 66 M 2?88 1?
AS 70 M 3?35 1?
DS 62 F 1?99 0?
HW 65 M 3?00 0?
SC 62 F 2?31 0?
S: salbutamol; I: ipratropium; B: beclomethasone inhalers; P: ppatient (EL) had a mean baseline FEV1 of 65% predicted.
The patients had no other concurrent medical problems and
had had no respiratory infection for at least 1 month prior
to study. Any inhaled or oral steroids were continued as
usual but inhaled BDs were withheld for 4 h and oral BDs
for 24 h on study days. All patients gave informed verbal
consent to the study, which had the approval of Guys and
Lewisham Hospitals Ethics Committee.
PROTOCOL 1
This was a randomized, cross-over study with two study
days within a 3-week period. On each day, patients were
given placebo aerosol in order to practice the method of
inhalation before any measurements were made. Then, after
baseline measurements had been made, 1?5 mg terbutaline
and 0?12 mg ipratropium bromide were inhaled from MDIs
(six actuations each) via a nebuhaler, wiped with an anti-
static cloth before use. Before each actuation the inhalers
were shaken vigorously. On one of the days, patients
inhaled the aerosols from the nebuhaler using two
maximum breaths, from residual volume to total lung
capacity, with a 10-sec breath-hold after each breath. On
the other day they inhaled the aerosol using six tidal breaths
per puff.
The measurements, made at baseline and 40 min after
medication, were as follows: the mean was taken of 10
measurements of airways resistance (Rint), made inMean baseline values
1 (l) VC (l) SVC (l) 6MWD Drugs
59 1?51 1?76 164 S, A, P
86 1?97 2?30 559 S, A
83 2?51 3?11 466 S, I
86 2?52 3?11 461 S, I
72 2?16 2?33 343 S, I, A, D
22 2?68 2?64 467 S, A
19 2?87 2?80 504 S, I, B
67 1?73 1?82 237 S, I, B
81 1?86 2?12 453 S, A, B
66 4?74 4?70 640 S, A
62 1?78 2?45 512 S
33 3?83 3?89 218 S, I, B
70 1?89 2?78 209 S
56 4?17 4?31 565 S, I, A
86 2?01 2?42 309 S
15 2?60 3?19 490 S
48 3?26 3?55 296 S, B
67 2?08 2?26 269 S
71 1?89 2?52 510 S, A
85 2?07 2?30 526 S, I, A, B, D
rednisone; A: aminophylline; D: diuretic oral.
478 N. M. EISER ET ALinspiration (Rintinsp) and in expiration (Rintexp), using a
portable interrupter device (Microlab 4000, Micromedical,
Rochester, U.K.). Following this, FEV1, forced vital
capacity (FVC) and slow vital capacity (SVC) were
measured with a dry spirometer (Vitalograph, Rochester,
U.K.). This best of three technically satisfactory measure-
ments was taken. After a 10-min rest, a 6-min walking test
(6MWD) was undertaken along indoor hospital corridors.
The patients were accompanied by the investigator who
walked in front, encouraging the subjects both to walk as
fast as they were able and to restart as soon as possible if
they had stopped. At the end of the walks, exertional
dyspnoea was recorded on a Borg scale and on a 100-mm
visual analogue scale (VAS), with 0 as normal breathing
and 100 mm as the worst imaginable breathlessness.
PROTOCOL 2
Nine of these COPD subjects undertook a further dose–
response study on two extra days. On the first day, they
performed a practice incremental shuttle walking test
(shuttle) and then, after 30 min rest, they performed
baseline lung function (spirometry, SVC and inspiratory
capacity) and another shuttle. These tests were repeated 40
min after terbutaline 500 mg and iptratropium bromide
40 mg given via the nebuhaler. Following another 30-min
rest, a further dose of terbutaline 1?0 mg and iptratropium
bromide 80 mg was given and all the measurements were
made again 40 min later.
On the second day, the protocol was repeated except that
a final testing was performed following nebulized terbuta-
line 5 mg with ipratropium bromide 0?5 mg. Four of the
patients took their BDs via the tidal breathing method on
day 1 and via maximal breaths on day 2, whilst five patients
did the maximal breath method on day 1 and the tidal
breathing method on day 2.
STATISTICAL ANALYSIS
Medians and ranges of all measurements are presented. The
Wilcoxon rank test was used to compare post-BD with
baseline values of all measurements and also to compare
the changes occurring after the different methods of
inhalation for both protocols.
Results
FIRST PROTOCOL: COMPARING TIDAL
AND MAXIMAL BREATHS FOR SIX PUFFS
OF BD
Two patients developed chest infections and did not
complete the study, leaving 20 patients for evaluation.
Table 2 shows the individual results of all 20 patients.
Median values and ranges are given. Wilcoxon rank testing
confirmed that there were highly statistically significant
increases in FEV1, FVC, SVC and also in 6MWD following
both methods of inhaling BDs from the MDI withnebuhaler. There were also highly significant decreases in
Rintinsp and Rintexp (0?45 to 0?28 kPa sI
71 and 0?48 to
0?34 kPa sI71, respectively, P=0?003) and smaller improve-
ments in VAS and Borg for post-exertional dyspnoea scores
(71?5 to 65?5 mm and 5–4, respectively, P=0?04).
Comparing maximal and tidal breathing methods (Fig. 1),
there were no significant differences in any of the changes in
spirometric measurements or in the walking distances.
However, VAS exertional dyspnoea score improved more
with the tidal breathing method than with maximal breaths.
All subjects preferred the tidal breathing technique
compared with the maximal breath with breath-hold and
found it much easier to learn and perform.
SECOND PROTOCOL: DOSE–RESPONSE
COMPARISONS
The results are displayed in Table 3. Comparing tidal
breathing and maximal breath techniques, there were no
statistically significant differences in lung function or
shuttle. This holds true for baseline values, as well as after
two and six puffs from the two aerosols.
Dose–response results
After two puffs from both inhalers using the tidal breathing
method, there were statistically significant improvements in
FEV1, VC and SVC (P50?02) and in shuttle (P=0?008).
After six puffs, there was a small, further, significant
improvement in FEV1 only (P=0?044). Although there was
no significant difference in spirometry comparing responses
to six puffs of the aerosols and nebulized bronchodilators,
the shuttle continued to improve slightly from 34 after six
puffs to 36 shuttles after nebulized BDs (P=0?0117).
Using the maximal breath technique, two puffs of the
aerosols produced significant improvements in the shuttle
(P=0?008) and in spirometry (for FEV1, P=0?017; for VC
P=0?01; for SVC P=0?036). Between two and six puffs of
the aerosols there were small, but nevertheless significant,
dose-related increases in FEV1 (P=0?02) and shuttle
(P=0?012). However, only the shuttle improved signifi-
cantly between six puffs of the aerosols and nebulizer (33–
36 shuttles, (P=0?0357).
Individual results
There were increases in FEV1 of 200 ml or more in:
. One patient comparing two with six puffs of aerosols
for tidal breathing and two patients for maximal
breaths;
. No patients comparing six puffs of aerosols with
nebulizer for either technique;
. Two patients comparing two puffs of aerosols with
nebulizer for maximal breaths and zero for tidal
breathing;
. There were no differences for two puffs of aerosol
comparing maximal and tidal breaths.
TABLE 2. Comparison of individual patient responses for maximal breaths and for tidal breaths
Two maximal breaths with breath-hold Six tidal breaths
FEV1 FVC SVC 6MWD FEV1 FVC SVC 6MWD
Patient Baseline Post-BD Baseline Post-BD Baseline Post-BD Baseline Post-BD Baseline Post-BD Baseline Post-BD Baseline Post-BD Baseline Post-BD
1 0?60 0?60 1?41 1?60 1?60 2?00 142?2 161?0 0?61 0?61 1?55 1?77 1?77 1?99 167?9 183?5
2 0?80 1?00 1?90 2?20 2?40 2?20 563?0 543?3 0?89 0?99 2?11 2?22 2?22 2?44 540?6 566?2
3 0?80 1?10 2?40 3?30 3?10 3?90 438?6 513?5 0?78 0?99 2?22 3?33 2?88 3?38 458?2 539?1
4 0?78 0?94 2?20 2?88 2?88 3?44 428?7 467?0 0?90 0?94 2?90 2?90 3?32 3?54 474?3 492?6
5 0?78 0?89 2?44 2?66 2?44 2?77 359?6 376?8 0?70 0?80 1?80 2?22 2?10 2?60 322?7 364?6
6 1?22 1?33 2?87 2?67 2?65 2?87 468?9 494?6 1?33 1?60 2?70 2?90 2?70 2?90 478?0 504?0
7 1?03 1?33 2?45 3?21 2?30 2?86 459?4 501?8 1?22 1?45 3?01 3?56 2?78 3?56 534?0 520?9
8 0?67 0?89 1?67 2?23 1?78 2?45 231?8 306?4 0?78 0?78 1?77 2?00 2?00 2?22 206?8 273?0
9 0?89 1?11 1?89 2?20 2?23 2?67 435?0 482?2 0?78 1?11 2?00 2?33 2?33 2?66 427?2 498?8
10 1?66 1?77 4?55 5?10 4?77 5?21 646?2 664?2 1?66 1?77 4?88 4?88 4?88 5?10 635?5 654?4
11 0?67 0?72 1?78 2?23 2?45 2?78 493?5 544?3 0?56 0?67 1?78 2?00 2?45 2?89 531?1 568?6
12 1?44 1?77 4?21 4?77 4?21 4?44 241?2 283?0 1?22 1?56 3?45 4?67 3?56 4?79 195?3 255?1
13 0?67 1?00 1?78 3?00 2?67 3?56 178?2 396?1 0?72 0?89 2?00 2?89 2?89 3?12 239?4 377?2
14 2?67 3?12 4?23 4?34 4?34 4?34 550?6 584?4 2?44 3?22 4?00 4?55 4?33 4?55 587?2 621?6
15 0?89 1?11 2?00 2?44 2?66 2?77 312?8 377?1 0?78 1?12 2?01 2?62 2?34 2?90 297?8 380?1
16 1?11 1?44 2?44 3?05 3?11 3?33 502?3 491?0 1?23 1?56 2?68 3?35 3?12 3?79 450?3 507?7
17 1?55 2?00 3?44 4?00 3?55 4?44 306?1 417?7 1?45 2?00 3?34 4?34 3?78 4?45 321?3 406?6
18 0?67 0?78 2?01 2?34 2?23 2?46 203?7 226?7 0?67 0?72 2?22 2?44 2?33 2?66 288?2 352?3
19 0?67 1?00 2?00 2?67 2?45 3?67 419?7 543?4 0?67 1?00 1?66 2?88 2?44 3?55 555?3 601?5
20 0?89 1?00 1?99 2?22 2?22 2?44 493?0 517?2 0?89 1?00 2?33 2?44 2?44 2?44 557?8 585?4
Median 0?85 1?05 2?11 2?67 2?55 2?87 431?9 486?6 0?84 1?00 2?22 2?89 2?58 3?01 454?3 501?4
Range 0?60–2?67 0?60–3?10 1?41–4?55 1?60–5?10 1?60–4?77 2?00–4?44 142–646 161–664 0?60–2?44 0?61–3?22 1?55–4?88 1?77–4?88 1?77–4?88 1?99–5?10 168–636 184–654
Pwilcoxon * * ** * * ** * * * * ** * * * * * * * * * * * *












































FIG. 1. Effects of bronchodilators given by MDI via a nebuhaler on FEV1, FVC, SVC, Rint, 6MWD and post-exertional
dyspnoea measured by Borg score and by VAS. Median post-BD change are shown. With the exception of the VAS score,
there is no significant difference using two maximal breath (&) or six tidal breaths ( ) per puff. **P50?001 from Wilcoxon
rank testing.
480 N. M. EISER ET ALThere were increases in FVC of 200 ml or more in:
. Three patients using both techniques comparing two
with six puffs of aerosols;
. Three patients for tidal breaths and two for maximal
breaths comparing six puffs of aerosols with nebulizer;
. Three patients for tidal breaths and six for maximal
breaths comparing two puffs of aerosols with
nebulizer;
. Four patients tidal breathing and one for maximal
breaths comparing two puffs of aerosols with the two
techniques.
There were increases of four shuttles or more on exercise
testing in:
. Two patients for tidal breaths and four patients for
maximal breaths comparing two with six puffs of
aerosols;
. Four patients for tidal breaths and two for maximal
breaths comparing six puffs of aerosols with nebulizer;
. Two patients for tidal breaths and six for maximal
breaths comparing two puffs of aerosols with
nebulizer;
. Two patients for tidal breaths and one for maximal
breaths comparing two puffs of aerosols with the two
techniques.
SIDE-EFFECTS
None of the subjects experienced any significant side-effects
from any of the doses of BDs given in this study.Discussion
ELECTROSTATIC CHARGES
It is generally agreed that spacing devices improve lung
deposition of aerosols generated by MDI devices as well as
increasing bronchodilatation in normal and asthmatic
adults and children (4–9,11). Results from recent studies
have suggested that the output of drugs from spacing
devices is affected by the development of electrostatic
charges and that these can be reduced by wiping the inside
of the devices with an anti-static cloth (12,13). This
precaution was taken in our study.
TIDAL BREATHING VERSUS MAXIMAL
BREATHS VIA SPACER
We have routinely prescribed spacers with MDIs to patients
with COPD but many, particularly those with the most
severe airflow limitation, have found that the maximal
breaths and, in particular, the breath-holds were dicult to
execute. In one paediatric asthma study, a panting
manoeuvre was as effective as a single breath with breath-
hold when inhaling 200 mg salbutamol from an MDI and
volumatic (14). Various spacing devices, including nebu-
halers and polystyrene coffee cups, have been found useful
in the management of acute asthma in young children.
Since these patients benefited from the BDs when inhaled
by the tidal breathing method, we have investigated this
method in our patients with COPD. Although our patients
were moderately severely disabled with dyspnoea, the
combined effect of the BDs produced highly significant
TABLE 3. Comparison between bronchodilator effects of two and six puffs of terbutaline and ipratropium bromide aerosols from MDI and spacer using maximal breath with
breath-hold and six tidal breaths and also with nebulized terbutaline and ipratropium aerosols
Maximal breaths Tidal breaths Nebulizer
Baseline Two puffs Six puffs Baseline Two puffs Six puffs
Median Range Median Range Median Range Median Range Median Range Median Range Median Range
FEV1 1?00 0?59–1?54 1?05 0?62–1?51 1?14 0?76–2?06 0?80 0?70–1?39 1?08 0?65–1?84 1?13 0?66–2?06 1?22 0?68–2?17
FVC 2?24 1?64–3?71 2?90 1?41–3?88 3?04 1?50–4?03 2?25 1?52–3?98 2?72 1?67–3?79 3?06 1?71–4?23 3?06 1?61–4?32
SVC 3?18 1?70–4?20 3?18 1?83–4?41 3?54 1?95–4?36 2?76 1?86–4?02 3?12 1?82–4?36 3?42 1?95–4?72 3?50 1?89–4?42
IC 1?85 1?02–2?96 2?10 1?15–3?25 2?16 1?27–3?09 1?63 0?45–2?98 2?19 1?14–3?62 2?03 1?15–3?20 2?10 1?20–3?27
Shuttle 23 11–46 30 14–51 34 18–56 28 8–42 32 16–56 33 18–55 36 21–58
VAS 65 38–71 57 40–67 58 30–78 58 45–82 58 26–77 65 37–78 64 45–77











































482 N. M. EISER ET ALimprovements in spirometry in statistical terms. In protocol
1, six puffs of each BD produced a mean FEV1 increase of
more than 200 ml or 8–9% of predicted, and there was a
nearly 500 ml improvement in FVC (15% of predicted
normal). This was accompanied by a useful improvement in
exercise tolerance; the walking distance increasing by 15–
18%. Although there was no significant difference between
tidal breathing and maximal breath results but the patients
found the tidal breathing method easier and more pleasant.
However, it could be argued that the six puffs of both
terbutaline (1?5 mg) and ipratropium bromide (0?12mg)
used in protocol 1 was higher than the normal therapeutic
dose and that the plateau of response may have been
reached, making it dicult to distinguish the effects of
different modes of inhalation. For this reason, protocol 2
compared the effects of the two modes of inhalation after
two puffs as well as six puffs of each BD. Even at this
smaller, clinical dose of BD, no significant different effects
were detected between the two modes of inhalation for the
group as a whole. In addition, no individual had a clinically
significant difference in FEV1 response (15) to the two
modes of inhalation. However, FVC and exercise tolerance
improved more with tidal breathing than with maximal
breaths after two puffs of BD aerosols in a few of the
patients.
There were small, statistically significant, dose-related
improvements in lung function between two and six puffs
from the inhalers for the group as a whole, but only three
individuals demonstrated a clinically significant increase in
spirometry and only four had a significant improvement in
exercise tolerance. Clearly, therefore, we were near the top
of the plateau of the dose–response curve with two puffs as
well as the six puffs of BDs which had been used in protocol
1. Similar results were found with 6MWD in protocol 1 and
the shuttle in protocol 2.
NEBULIZERS VERSUS MDI WITH SPACERS
IN COPD PATIENTS
Spacers can be as effective as nebulizers in delivering
aerosol in the airways of patients with airflow obstruction.
There is now abundant information concerning both the
dose–response characteristics of BDs and also the differ-
ences in response found when they are delivered from either
nebulizers or MDIs (plus or minus spacers) (16-24). Most
of these studies have shown little difference in the acute or
domicillary effects of b2-agonists and anti-cholinergic
agents given in clinical doses from an MDI compared with
those from the larger nebulized doses. In our study there
were no statistically significant improvements in lung
function for the group as a whole, comparing nebulized
BD with two or six puffs given by tidal breathing, although
a few individuals increased their FVC by 200 ml or more.
However, after nebulized BD, the whole COPD group
showed a statistically significant improvement in exercise
tolerance and three individuals improved their exercise
tolerance by four or more shuttles.
In conclusion, in our patients with moderately severe but
stable COPD, similar effects on lung function and walkingdistance resulted whether six tidal breaths or two maximal
breaths with breath-hold were used to inhale the BDs from
MDIs plus spacer. This was true for both 500 mg terbutaline
with 40 mg iptratropium bromide (two puffs each) or for
terbutaline 1?5 mg with iptratropium bromide 0?12 mg
(six puffs each). Thus, six tidal breaths from a spacer and
MDI is a satisfactory alternative technique to the conven-
tional two maximal breaths with breath-hold which so
many patients find dicult. Either the tidal breathing or
maximal breath techniques from MDI and spacer can be
used as an alternative to the much more costly nebulized
solution in most patients with stable COPD, although
individual therapeutic trials may help to identify the
minority who benefit by improved exercise tolerance with
nebulized BDs.
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